Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07091630 · ClinicalTrials.gov registry record · Phase 3

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

A Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP, sponsored by argenx.

Recruiting
Registry status
Phase 3
Development phase
160
Enrollment target
19
Study locations

NCT07091630: Recruiting Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP, sponsored by argenx.

NCT07091630 is a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP that is actively recruiting participants, run by argenx. The registered enrollment target is 160 participants, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (10% higher). The trial reports 19 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07091630, a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP, is actively recruiting participants, sponsored by argenx.

RECRUITING
Registry status
Phase 3
Development phase
160 participants
Enrollment target
19
Study locations

Study Summary

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emnergize

Primary Outcome

The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

Conditions Studied

Chronic Inflammatory Demyelinating Polyneuropathy CIDP Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Interventions

  • BIOLOGICAL Empasiprubart IV
  • OTHER Placebo IV

Study Locations (19)

Other

  • Peking University First Hospital - Changqiao Campus - Beijing
  • Nanfang Hospital Southern Medical University - Guangzhou
  • High Technology Hospital MedCenter Ltd - Batumi
  • First Medical Clinic LLC - Batumi
  • Petre Sarajishvili Institute of Neurology - Tbilisi
  • Aleksandre Aladashvili Clinic - Tbilisi
  • Curatio JSC - Tbilisi
  • LTD New Hospitals - Tbilisi
  • Geo Hospitals - Tbilisi
  • Jo Ann Medical Center - Tbilisi
  • Southern TOHOKU Medical Clinic - Kōriyama
  • Seoul National University Hospital - Seoul
  • Korea University Guro Hospital - Seoul

Texas

  • National Neuromuscular Research Institute - Austin
  • NeuroCarePlus - Houston

Colorado

  • Colorado Springs Neurological Associates - Colorado Springs

District of Columbia

  • Medstar Health Research Institute - Washington D.C.

Florida

  • Gables Neurology - Miami

Louisiana

  • Paradigm Health System - Slidell

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2025-09-16
Est. Completion 2031-01-23
Phase Phase 3
argenx

49 total trials

What NCT07091630 shows while recruiting

NCT07091630 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (10% higher).

The record links to 3 conditions, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 2 interventions - of which Empasiprubart IV is the first listed.

NCT07091630 lists 19 locations in 6 states (Other, Texas, Colorado).

Frequently Asked Questions

What is clinical trial NCT07091630 about?

NCT07091630 is a clinical study titled "A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP". The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all partici...

What is the current status of trial NCT07091630?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2025-09-16. Estimated completion is 2031-01-23.

What conditions does trial NCT07091630 study?

This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

What interventions are being tested in trial NCT07091630?

The interventions under investigation include: Empasiprubart IV (BIOLOGICAL), Placebo IV (OTHER).

Who is sponsoring clinical trial NCT07091630?

This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07091630 being conducted?

This trial has 19 study locations across Colorado, District of Columbia, Florida, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07091630's enrollment target sits among peer trials

160 6th of 11 higher than 5 of 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Inflammatory Demyelinating Polyneuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07091630

Source: ClinicalTrials.gov NCT07091630, the US trial registry maintained by the National Library of Medicine. NCT07091630 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.